Company Profile

Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors. It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors. The company was founded in 1996 and is headquartered in Sovicille, Italy.

Latest News

Goldman Sachs leads oil and gas M&A advisory by value in H1 2026

Offshore Technology • 07/27/2026

Philippines' Marcos says 'perhaps time to revisit nuclear energy'

AFP • 07/27/2026

Camden National Bank Earnings: What To Look For From CAC

StockStory • 07/27/2026

Black Book Expands Vendor-Agnostic Healthcare Supply Chain Technology Benchmark to 36 Categories for AHRMM26

ACCESS Newswire • 07/27/2026

Target Hospitality Announces New $660 Million Credit Facility, Significantly Expanding Liquidity and Lowering Cost of Capital to Support Strategic Growth

PR Newswire • 07/27/2026